Antiparasitical chemotherapy in Chagas’ disease cardiomyopathy: current evidence
Chronic chagasic cardiomyopathy affects 20% of Chagas’ disease patients. At present, Chagas’ disease chemotherapy uses nitrofurans, benznidazole (Rochagan®, Rodanil®, Roche) or nifurtimox (Lampit®, Bayer). Treatment during acute and recent chronic phases in childhood effects 71.5% and 57.6%, respectively, of parasitological cure. However, in clinical trials during the late chronic phase, only 5.9% of parasitological cure were achieved. This review focuses on the benefit from aetiological treatment to avoid, stop or revert myocarditis. Divergent data gathered from clinical practice are not convincing to support prescription of aetiological treatment as routine for indeterminate and cardiac chronic patients.
Document Type: Research Article
Affiliations: 1: Department of Microbiology and Parasitology, Bioscience Center, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil 2: School of Medicine, University Antonio Nariño, Bogotá, Colombia 3: Department of Biochemistry and Immunology, Medicine School at Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil 4: Laboratory of Cellular Ultrastructure, Oswaldo Cruz Institute-FIOCRUZ, Rio De Janeiro, Rio de Janeiro State, Brazil
Publication date: 2012-09-01